Patents by Inventor Marc HYER

Marc HYER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Administration of ubiquitin-activating enzyme inhibitor and radiation
    Patent number: 10335411
    Abstract: Disclosed are methods for the treatment of cancer in patients in need of such treatment. The methods comprise administering to such a patient an ubiquitin-activating enzyme (UAE) inhibitor such as ((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-(3-(trifluoromethylthio) phenyl)pyrazolo[1,5-a]pyrimidin-7-ylamino)cyclopentyl)methyl sulfamate (Compound 1) or a pharmaceutically acceptable salt in combination with radiation. Also disclosed are medicaments for use in the treatment of cancer.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: July 2, 2019
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Neil Bence, Marc Hyer, Michael Milhollen, Vivek Samnotra, Sergio Luis Santillana Soto, Darshan Sappal
  • COMBINATION THERAPIES OF HER2-TARGETED ANTIBODY-DRUG CONJUGATES
    Publication number: 20180271996
    Abstract: Disclose herein are combinations comprising HER2-targeted antibody-drug conjugates and immune checkpoint inhibitors and methods of using such combinations in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Application
    Filed: February 27, 2018
    Publication date: September 27, 2018
    Applicants: Mersana Therapeutics, Inc., Millennium Pharmaceuticals Inc.
    Inventors: Natalya D. BODYAK, Donald A. BERGSTROM, Marc HYER, Timothy B. LOWINGER, Marina PROTOPOPOVA, Ole Petter VEIBY, Aleksandr V. YURKOVETSKIY, Qing Xiu ZHANG
  • ADMINISTRATION OF UBIQUITIN-ACTIVATING ENZYME INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
    Publication number: 20180133221
    Abstract: Disclosed are methods for the treatment of cancer in patients in need of such treatment. The methods comprise administering to such a patient an ubiquitin-activating enzyme (UAE) inhibitor such as ((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-(3-(tri-fluoromethylthio)phenyl)pyrazolo [1,5-a]pyrimidin-7-ylamino)cyclopentyl)methyl sulfamate (Compound 1) or a pharmaceutically acceptable salt in combination with one or more chemotherapeutic agents. Also disclosed are medicaments for use in the treatment of cancer.
    Type: Application
    Filed: October 23, 2015
    Publication date: May 17, 2018
    Inventors: Neil BENCE, Jessica HUCK, Marc HYER, Michael MILHOLLEN, Judy Qiuji SHI, Tary TRAORE
  • ADMINISTRATION OF UBIQUITIN-ACTIVATING ENZYME INHIBITOR AND RADIATION
    Publication number: 20170333434
    Abstract: Disclosed are methods for the treatment of cancer in patients in need of such treatment. The methods comprise administering to such a patient an ubiquitin-activating enzyme (UAE) inhibitor such as ((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-(3-(trifluoromethylthio) phenyl)pyrazolo[1,5-a]pyrimidin-7-ylamino)cyclopentyl)methyl sulfamate (Compound 1) or a pharmaceutically acceptable salt in combination with radiation. Also disclosed are medicaments for use in the treatment of cancer.
    Type: Application
    Filed: October 23, 2015
    Publication date: November 23, 2017
    Inventors: Neil BENCE, Marc HYER, Michael MILHOLLEN, Vivek SAMNOTRA, Sergio Luis SANTILLANA SOTO, Darshan SAPPAL